VERU INC. Line of Credit, Current
VERU INC. (VERU) had Line of Credit, Current of $884.92 thousand as of 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:LinesOfCreditCurrent · last filed 2021-12-02
- 2021-06-30: Line of Credit, Current $884.92K.
- 2021-03-31: Line of Credit, Current $4.47M.
- 2020-12-31: Line of Credit, Current $5.33M.
- 2020-09-30: Line of Credit, Current $5.84M.
| Period end | Line of Credit, Current |
|---|---|
| 2021-06-30 | $884.92K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $4.47M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $5.33M 10-Q · filed 2021-02-10 |
| 2020-09-30 | $5.84M 10-K · filed 2021-12-02 |
| 2020-06-30 | $6.60M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $6.66M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $6.55M 10-Q · filed 2020-02-12 |
| 2019-09-30 | $5.39M 10-K · filed 2020-12-10 |
| 2019-06-30 | $4.66M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $5.84M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $4.94M 10-Q · filed 2019-02-13 |
| 2018-09-30 | $6.69M 10-K · filed 2019-12-12 |
| 2018-06-30 | $6.43M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $3.91M 10-Q · filed 2018-05-11 |
| 2015-06-30 | $0.00 10-Q · filed 2015-07-30 |
| 2014-09-30 | $0.00 10-Q · filed 2015-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |